Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Creeping Eruption Treated With Thiabendazole

Creeping Eruption Treated With Thiabendazole Abstract Members of the Jacksonville Dermatology Society have treated 51 patients with active creeping eruption with oral thiabendazole. No single- or double-blind placebo controls were used. There were no severe toxic reactions from the drug in the dosage of 25 mg/kg of body weight twice a day. Observation during the patients' hospitalization and results of their laboratory tests lead us to believe that thiabendazole is a relatively safe drug and might be given without hospitalization of the patient. Our results to date have been encouraging for a disease that hitherto has had no satisfactory treatment. Even the seven cases that did not respond entirely received no less than a "good" rating by both doctor and patient. The posttreatment follow-up ranged from one week to one month. During this time none of 44 responsive patients developed relapses of their disease. In our program 25 mg/kg of body weight for 3 to 4 days seems the best treatment schedule. References 1. Kirby-Smith, J. L.; Dove, W. E.; and White, F. G.: Creeping Eruption , Arch Derm 13:137 ( (Feb) ) 1926.Crossref 2. Sompayrac, L. M.: Creeping Eruption, SMA , Southern Med J 47:792 ( (Aug) ) 1954.Crossref 3. Stone, O. J., and Mullins, J. F.: First Use of Thiabendazole in Creeping Eruption , Texas Rep Biol Med 21:422-424, 1963. 4. Stone, O. J., and Mullins, J. R.: Thiabendazole Therapy for Creeping Eruption , Arch Derm 89:557-559 ( (April) ) 1964.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Creeping Eruption Treated With Thiabendazole

Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/creeping-eruption-treated-with-thiabendazole-KgG0w6Eabb

References (4)

Publisher
American Medical Association
Copyright
Copyright © 1965 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1965.01600110011003
Publisher site
See Article on Publisher Site

Abstract

Abstract Members of the Jacksonville Dermatology Society have treated 51 patients with active creeping eruption with oral thiabendazole. No single- or double-blind placebo controls were used. There were no severe toxic reactions from the drug in the dosage of 25 mg/kg of body weight twice a day. Observation during the patients' hospitalization and results of their laboratory tests lead us to believe that thiabendazole is a relatively safe drug and might be given without hospitalization of the patient. Our results to date have been encouraging for a disease that hitherto has had no satisfactory treatment. Even the seven cases that did not respond entirely received no less than a "good" rating by both doctor and patient. The posttreatment follow-up ranged from one week to one month. During this time none of 44 responsive patients developed relapses of their disease. In our program 25 mg/kg of body weight for 3 to 4 days seems the best treatment schedule. References 1. Kirby-Smith, J. L.; Dove, W. E.; and White, F. G.: Creeping Eruption , Arch Derm 13:137 ( (Feb) ) 1926.Crossref 2. Sompayrac, L. M.: Creeping Eruption, SMA , Southern Med J 47:792 ( (Aug) ) 1954.Crossref 3. Stone, O. J., and Mullins, J. F.: First Use of Thiabendazole in Creeping Eruption , Texas Rep Biol Med 21:422-424, 1963. 4. Stone, O. J., and Mullins, J. R.: Thiabendazole Therapy for Creeping Eruption , Arch Derm 89:557-559 ( (April) ) 1964.Crossref

Journal

Archives of Dermatology – American Medical Association

Published: May 1, 1965

There are no references for this article.